Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Article English OPEN
Mullins, James I.; Heath, Laura; Hughes, James P.; Kicha, Jessica; Styrchak, Sheila; Wong, Kim G.; Rao, Ushnal; Hansen, Alexis; Harris, Kevin S.; Laurent, Jean-Pierre; Li, Deyu; Simpson, Jeffrey H.; Essigmann, John M.; Loeb, Lawrence A.; Parkins, Jeffrey;
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE,volume 6,issue 1 (issn: 1932-6203, eissn: 1932-6203)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.1371/journal.pone.0015135, pmc: PMC3021505
  • Subject: Antivirals | Research Article | Biology | Clinical Research Design | Infectious Diseases | Genetic Mutation | Microbiology | Medicine | Viral Diseases | Immunodeficiency Viruses | Viral Replication | Q | Microbial Mutation | R | Genetics | HIV | Virology | Science | Clinical Trials | Viral Nucleic Acid

The deoxycytidine analog KP1212, and its prodrug KP1461, are prototypes of a new class of antiretroviral drugs designed to increase viral mutation rates, with the goal of eventually causing the collapse of the viral population. Here we present an extensive analysis of v... View more
Share - Bookmark